Should we still subcategorize Helicobacter pylori-associated dyspepsia as functional disease?

Journal of Neurogastroenterology and Motility

Volumn 17, Issue 4, 2011, Pages 366-371

  Sugano, Kentaro ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Dyspepsia; Functional dyspepsia; Gastric acid; Helicobacter pylori; Ulcer

Indexed keywords

EID: 80054953709     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm.2011.17.4.366     Document Type: Short Survey

References (54)

1. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. In: Drossman DA senior, ed. Rome III The functional gastrointestinal disorders. 3rd ed. McLean, Virginia: Degnon Associates, Inc 2006:420-425.
2. Lu CL, Chang SS, Wang SS, Chang FY, Lee SD. Silent peptic ulcer disease: frequency, factors leading to "silence," and implications regarding the pathogenesis of visceral symptoms. Gastrointest Endosc 2004;60:34-38.
3. Wand FW, Tu MS, Mar GY, et al. Prevalence and risk factors of asymptomatic peptic ulcer disease in Taiwan. World J Gastroenterol 2011;17:1199-1203.
4. Gilvary J, Buckley MJ, Beattie S, Hamilton H, O'Morain CA. Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia. Scand J Gastroenterol 1997;32:535-540.
5. McColl K, Murray L, El-Omar E, et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1869-1874.
6. Blum AL, Talley NJ, O'Moráin C, et al. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1875-1881.
7. Hsu PI, Lai KH, Lo GH, et al. Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients. Gut 2002;51:15-20.
8. Moayyedi P, Decks J, Talley NJ, Delaney B, Forman D. An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003;98:2621-2626.
9. Talley NJ, Janssens J, Lauritsen K, Rácz I, Bolling-Sternevald E. Eradication of Helicobacter pylori in functional dyspepsia: randomized double blind placebo controlled trial with 12 months' follow up. BMJ 1999;318:833-837.
10. Talley NJ, Vakil N, Ballard ED 2nd, Fennerty MB. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 1999;341:1106-1011.
11. Miwa H, Hirai S, Nagahara A, et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients-a double-blind placebo-controlled study. Aliment Pharmacol Ther 2000;14:317-324.
12. Froehlich F, Gonvers JJ, Wietlisbach V, et al. Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. Am J Gastroenterol 2001;96:2329-2336.
13. Koskenpato J, Farkkilä M, Sipponen P. Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia. Am J Gastroenterol 2001;96:2866-2872.
14. Hsu PI, Lai KH, Tseng HH, et al. Eradication of Helicobacter pylori prevents ulcer development in patients with ulcer-like functional dyspepsia. Aliment Pharmacol Ther 2001;15:195-201.
15. Bruley Des Varannes S, Fléjou JF, Colin R, Zaïm M, Meunier A, Bidaut-Mazel C. There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2001;15:1177-1185.
16. Malfertheiner P, MOssner J, Fischbach W, et al. Helicobacter eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther 2003;18:615-625.
17. Koelz HR, Amold R, Stolte M, Fischer M, Blum AL, FROSCH Study Group. Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: a double blind randomized trial with a six month follow up. Gut 2003;52:40-46.
18. Gisbert JP, Cruzado AI, Garcia-Gravalos R, Pajares JM. Lack of benefit of treating Helicobacter pylori infection in patients with functional dyspepsia. Randomized one-year follow-up study. Hepatogastroenterology 2004;51:303-308.
19. Talley NJ, Meineche-Schmidt V, Paré P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998;12:1055-1065.
20. Farup PG, Hovde O, Trop R, Wetterhus S. Patients with functional dyspepsia resopinding to omeprazole have a characteristic gastro-oesophageal reflux pattern. Scand J Gastroenterol 1999;34:575-579.
21. Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status. Gut 2000;47:473-480.
22. Bolling-Sternevald E, Lauritsen K, Aalykke C, et al. Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 2002;37:1395-1402.
23. Wong WM, Wong BC, Hung WK, et al. Double blind, randomized, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002;51:502-506.
24. Peura DA, Kovacs TO, Metz DC, Siepman N, Pilmer BL, Talley NJ. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med 2004;116:740-748.
25. Van Zanten SV, Armstrong D, Chiba N, et al. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized placebo-controlled "ENTER" trial. Am J Gastroenterol 2006;101:2096-2106.
26. Yeomans ND, Neasdal J. Systematic review: ulcer definition in NSAID ulcer prevention trials. Aliment Pharmacol Ther 2008;27: 465-472.
27. Ford AC, Marwaha A, Lim A, Moayyedi P. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8:830-837.e2.
28. Azuma T. Helicobacter pylori CagA protein variation associated withgastric cancer in Asia. J Gastroenterol 2004;39:97-103.
29. Yamaoka Y, Kato M, Asaka M. Geographic differences in gastric cancer incidence can be explained by differences between Helicoabacter strains. Inter Med 2008;47:1077-1083.
30. Miyamoto M, Haruma K, Yoshihara M, et al. Nodular gastritis in adults is caused by Helicobacter pylori infection. Dig Dis Sci 2003;48:968-975.
31. Dwivedi M, Misra SP, Misra V. Nodular gastritis in adults: clinical features, endoscopic appearance, histopathological features, and response to therapy. J Gastroenterol Hepatol 2008;23:943-947.
32. Murayama Y, Miyagawa J, Shinomura Y, et al. Morphological and functional restoration of parietal cells in Helicobacter pylori associated enlarged fold gastritis after eradication. Gut 1999;45:653-661.
33. Shimatani T, Inoue M, Iwamoto K, et al. Prevalence of Helicobacter pylori infection, endoscopic gastric findings and dyspeptic symptoms among a young Japanese population born in the 1970s. J Gastroenterol Hepatol 2005;20:1352-1357.
34. Yagi K, Aruga Y, Nakamura A, Sekine A. Regular arrangement of collecting venules (RAC): a characteristic endoscopic feature of Helicobacter pylori-negative stomach and its relationship with eophago-gastric adenocarcinoma. J Gastroenterol 2005;40:443-452.
35. Anagnostopoulos GK, Yao K, Kaye P, et al. High-resolution magnification endoscopy can reliably identigy normal gastric mucosa, Helicobacter pylori-associated gastritis, and gastric atrophy. Endoscopy 2007;39:202-207.
36. Amieva MR, El-Omar E. Host-bacterial interactions in Helicobacter pylori infection. Gastroenterology 2008;134:306-323.
37. Hurlimann N, Dür S, Schwab P, et al. Effects of Helicobacter pylori on gastritis, pentagastrin-stimulated gastric acid secretion, and mealstimulated plasma gastrin release in the absence of peptic ulcer disease. Am J Gastroenterol 1998;93:1277-1285.
38. McColl KE, el-Omar E, Gillen D. Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy. Br Med Bull 1998;54:121-138.
39. Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004;127:1329-1337.
40. Wang WH, Huang JQ, Zheng GF, et al. Effects of proton-pump inhibitors on functional dyspepsia: A meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol 2007;5:178-185.
41. Koike T, Ohara S, Sekine H, et al. Helicobacter pylori infection prevents erosive reflux esophagitis by decreasing gastric acid secretion. Gut 2001;49:330-334.
42. Osawa H, Nakazato M, Date Y, et al. Impaired production of gastric ghrelin in chronic gastritis associated with Helicobacter pylori. J Clin Endocrinol Metab 2005;90:10-16.
43. Ogiso K, Asakawa A, Amitani H, Inui A. Ghrelin: a gut hormonal basis of motility and functional dyspepsia. J Gastroenterol Hepatol 2011;26(suppl 3):67-72.
44. Iijima K, Ohara S, Sekine H, et al. Changes in gastric acid secretion assayed by endoscopic gastrin test before and after Helicobacter pylori eradication. Gut 2000;46:20-26.
45. +-adenosine triphosphatase expression without altering parietal cell number in human gastric mucosa. Gut 2006;55:152-157.
46. Osawa H, Kita H, Ohnishi H, et al. Changes in plasma ghrelin levels, gastric ghrelin production, and body weight after Helicobacter pylori cure. J Gastoenterol 2006;41:954-961.
47. Miyaji H, Azuma T, Ito S, et al. The effect of Helicobacter pylori eradication therapy on gastric antral myoelectrical activity and gastric emptying in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1999;13:1303-1309.
48. Matsumoto Y, Ito M, Kamino D, Tanaka S, Haruma K, Chayama K. Relation between histologic gastritis and gastric motility in Japanese patients with functional dyspepsia: evaluation by transabdominal ultrasonography. J Gastroenterol 2008;43:332-337.
49. 13C-octanoic acid breath test and the acetaminophen method. J Gastroenterol Hepatol 2006;21:824-830.
50. Jin X, Li YM. Systematic review and meta-analysis from Chinese literature: the association between Helicobacter pylori eradication and improvement of functional dyspepsia. Helicobacter 2007;12:541-546.
51. Stanghelini V, Barbara G, De Giorgio R, et al. Helicobacter pylori, mucosal inflammation and symptom perception-new insights into an old hypothesis. Aliment Pharmacol Ther 2001;15(suppl 1):28-32.
52. Turkkan E, Uslan I, Acarturuk G, et al. Does Helicobacter pylori-induced inflammation of gastric mucosa determine the severity of symptoms in functional dyspepsia? J Gastroenterol 2009;44:66-70.
53. Veijola L, Oksanen A, Linnala A, Sipponen P, Rautelin H. Persistent chronic gastritis and elevated Helicobacter pylori antibodies after successful eradication therapy. Helicobacter 2007;12:605-608.
54. Tack J, Talley NJ. Gastroduodenal disorders. Am J Gastroenterol 2010;105:757-763.